We are developing innovative gene therapies to treat Friedreich’s Ataxia (FA), a rare genetic condition, in collaboration with world-leading experts at UTSW. Dr Ryan Butler and Dr. Steven Gray, a pioneer in gene therapy, has already taken eight rare diseases to clinical trials and is helping us develop a breakthrough treatment for FA. Alongside him, Marek Napierala, and Jill Napierala, renowned experts in FA, are working together at UTSW to create life-changing therapies for patients.
Our mission is to provide hope and life-changing treatments for those affected by FA, particularly children. We are driven by the desire to save this generation, and we are working tirelessly to bring this treatment to FDA/EMA. We believe in the power of collaboration, and we need your support to make this happen. Your donations will help us accelerate our work and make a real impact.
We are determined to save lives and bring relief to families affected by Friedreich’s Ataxia. Together, we can make a difference and create a future where no child has to suffer from this devastating disease.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Krukmakargatan 50, Stockholm,stockholm County 11726,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.curefachildren.com
- Keywords
- Gene Therapy, Rare Disease Research, Friedreich´s Ataxia Treatment, Innovative Gene Therapies for Genetic Disorders, Rare Disease Treatment Development.
- HQ
- Stockholm, Stockholm County
- Competitors
- We Fizz, Fritidsbanken, Rituals (B Corp™), Ataxia Foundation.
Curefachildren Questions
Curefachildren's website is http://www.curefachildren.com
Curefachildren's LinkedIn profile is https://se.linkedin.com/company/curefachildren
Curefachildren has
1 employees.
View email and phone details for 1
employees at Curefachildren.
Curefachildren's industry is
Biotechnology Research
Curefachildren's categories are Biotechnology Research
Curefachildren's founding year is 2025
